Payment overview · 2025
General Payments
$496.63
26 reported records · 6 companies
Healthcare provider profile · identity verified
James Logan Casey, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BIRMINGHAM, AL · NPI 1134217821
Verified facts
What the public records show
CMS Open Payments records show James Logan Casey, M.D. received $496.63 in general payments during 2025 across 26 reported records.
PFIZER INC. accounted for 43.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $215.75 | 43.4% | 17 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $124.01 | 25.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $57.45 | 11.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.46 | 8.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.53 | 8.2% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.43 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $496.63 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $215.75 | 17 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $215.75 | 17 | 2025 |
Source payment records
|
|||||
| ESOPHYX Normalized: esophyx |
Device | Merit Medical Systems Inc | $124.01 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $57.45 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $40.53 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
161 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 777 | 215 |
| Pantoprazole Sodium | Pantoprazole Sodium | 486 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 441 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 422 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 367 | 98 |
| Losartan Potassium | Losartan Potassium | 358 | 104 |
| Metformin Hcl | Metformin Hcl | 316 | 86 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 296 | 84 |
| Montelukast Sodium | Montelukast Sodium | 285 | 89 |
| Omeprazole | Omeprazole | 280 | 80 |
| Chlorthalidone | Chlorthalidone | 273 | 82 |
| Simvastatin | Simvastatin | 271 | 71 |
| Furosemide | Furosemide | 263 | 86 |
| Potassium Chloride | Potassium Chloride | 258 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 240 | 73 |
| Jardiance | Empagliflozin | 238 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 236 | 46 |
| Gabapentin | Gabapentin | 230 | 60 |
| Zolpidem Tartrate | Zolpidem Tartrate | 226 | 41 |
| Lisinopril | Lisinopril | 212 | 59 |
| Clonazepam | Clonazepam | 209 | 51 |
| Ozempic | Semaglutide | 197 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 192 | 69 |
| Alprazolam | Alprazolam | 190 | 33 |
| Meloxicam | Meloxicam | 189 | 62 |
| Carvedilol | Carvedilol | 185 | 61 |
| Alendronate Sodium | Alendronate Sodium | 184 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 184 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 176 | 55 |
| Eliquis | Apixaban | 161 | 38 |
| Famotidine | Famotidine | 155 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 155 | 44 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 155 | 36 |
| Trazodone Hcl | Trazodone Hcl | 154 | 44 |
| Methocarbamol | Methocarbamol | 140 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 135 | 98 |
| Nifedipine Er | Nifedipine | 133 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 34 |
| Lorazepam | Lorazepam | 112 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 109 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 33 |
| Valsartan | Valsartan | 108 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 105 | 31 |
| Glimepiride | Glimepiride | 103 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 34 |
| Mounjaro | Tirzepatide | 97 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 29 |
| Allopurinol | Allopurinol | 92 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 27 |
| Celecoxib | Celecoxib | 80 | 23 |
| Prednisone | Prednisone | 80 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 25 |
| Farxiga | Dapagliflozin Propanediol | 79 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 19 |
| Ibuprofen | Ibuprofen | 76 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 23 |
| Methylprednisolone | Methylprednisolone | 75 | 63 |
| Sertraline Hcl | Sertraline Hcl | 75 | 23 |
| Tramadol Hcl | Tramadol Hcl | 75 | 13 |
| Atenolol | Atenolol | 74 | 19 |
| Bupropion Xl | Bupropion Hcl | 74 | 23 |
| Pregabalin | Pregabalin | 74 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 21 |
| Valacyclovir | Valacyclovir Hcl | 69 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 20 |
| Amoxicillin | Amoxicillin | 64 | 57 |
| Temazepam | Temazepam | 64 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 64 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 63 | 48 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 19 |
| Ezetimibe | Ezetimibe | 60 | 13 |
| Linzess | Linaclotide | 60 | 20 |
| Promethazine Hcl | Promethazine Hcl | 55 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 54 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 54 | 11 |
| Synthroid | Levothyroxine Sodium | 54 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 52 | 11 |
| Metformin Hcl Er | Metformin Hcl | 51 | 19 |
| Naproxen | Naproxen | 51 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 50 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 14 |
| Spironolactone | Spironolactone | 48 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 14 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Topiramate | Topiramate | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 24 |
| Azithromycin | Azithromycin | 44 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 21 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 43 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 42 | 17 |
| Aripiprazole | Aripiprazole | 41 | 11 |
| Fluconazole | Fluconazole | 40 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 39 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 12 |
| Colchicine | Colchicine | 38 | 12 |
| Diazepam | Diazepam | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 11 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 12 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Repaglinide | Repaglinide | 34 | suppressed |
| Baclofen | Baclofen | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 11 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 31 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 12 |
| Glipizide | Glipizide | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Testosterone | Testosterone | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | 11 |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 15 |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $496.63 · 26 records | PFIZER INC. | Dexcom G6 Transmitter, ENTRESTO, ESOPHYX, KRYSTEXXA, LEQVIO, NURTEC ODT, Veozah, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error